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Abstract
Background: To analyze the effects of BRCA1/2 mutations on chemotherapy response scores (CRS) and survival in a
cohort of patients with advanced-stage ovarian cancer who were treated with neoadjuvant chemotherapy (NAC)
followed by interval debulking surgery (IDS).
Methods: We retrospectively reviewed the medical records of 169 high-grade serous ovarian cancer patients who
underwent a germline BRCA1/2 test and received three cycles of NAC at the Yonsei Cancer Center from 2006 to
2018. Chemotherapy response scores were compared in patients with and without BRCA1/2 mutations. The effects
of BRCA1/2 mutations and CRS on survival were evaluated.
Results: BRCA1/2 mutations were detected in 47 (28.1%) of the 169 patients. Overall, 16 (34.0%) patients with
BRCA1/2 mutations had a CRS 3 to chemotherapy compared to scores of 43 in patients (35.2%) without a mutation.
Response scores of 3 in patients with BRCA1/2 mutations were not significantly associated with either improved
progression-free survival (PFS) (P = 0.949) or overall survival (OS) (P = 0.168). However, CRS 3 in patients without
BRCA mutations was significantly associated with both improved PFS (P = 0.030) and OS (P = 0.039). In patients with
CRS1/2, carriers of BRCA1/2 mutations had better PFS (P = 0.0344) and OS (P = 0.043) than wild-type BRCA genotype
patients.
Conclusion: In ovarian cancer patients treated with NAC, CRS did not predict survival for BRCA 1/2 mutation carriers
but did for BRCA wild-type patients.
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Background
Primary cytoreductive surgery followed by platinum-
based doublet chemotherapy has been considered stand-
ard treatment for advanced-stage ovarian cancer. How-
ever, several randomized clinical trials showed that their
survival outcomes and postoperative morbidity and
mortality after neoadjuvant chemotherapy (NAC)
followed by interval debulking surgery (IDS) were at
least as good as the results for patients who primary
cytoreductive surgery [1–4]. Recently, NAC followed by
IDS has become an alternative treatment for advanced-
stage ovarian cancer patients.
Bohm et al. proposed a three-tiered histopathologic
scoring system for grading the response to NAC [5]. A
three-tiered chemotherapy response scores (CRS) system
was applied to the omental tissue sections and correlated
with progression-free survival (PFS) [5, 6]. As a
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consequence, an increasing body of research has ad-
dressed whether CRS 3 can be used as a surrogate
marker, similar to the way the pathologic complete re-
sponse (pCR) is used in breast cancer, in the prognosis
for patients with advanced-stage ovarian cancer treated
with NAC followed by IDS. However, platinum-based
doublet chemotherapy remains the standard of care for
advanced-stage ovarian cancer patients who are treated
with NAC followed by IDS, regardless of their response
to chemotherapy.
Mutations in BRCA1 and BRCA2 have been recog-
nized as a predictor of advanced-stage ovarian cancer
susceptibility and a prognostic factor [7–9]. Compared
with wild-type BRCA genotype patients, patients with
advanced-stage ovarian cancer and BRCA1/2 mutations
have been reported to have higher clinical response rates
to platinum-based chemotherapy [10–12]. Therefore,
there are unanswered questions about whether the
higher CRS by carriers of the BRCA1/2 germline muta-
tions represents a better prognosis. In triple-negative
breast cancers treated with NAC, several studies have
tried to identify the relationships between germline
BRCA1/2 mutations, response rates, and prognoses [13,
14]. These studies have shown that patients with
BRCA1/2 mutations had superior response rates, and re-
sponse rate was a weaker predictor of disease-free sur-
vival rates compared with wild-type BRCA1/2 genotype
patients.
In this study, we analyzed the extent to which CRS
depended on germline BRCA1/2 mutations, whether
CRS correlates with platinum-based chemotherapy, and
whether CRS has an impact on survival outcomes in pa-
tients with and without germline BRCA1/2 mutations.
Methods
Study populations
We retrospectively reviewed the medical records of 326
patients with pathologically confirmed ovarian cancer
who from 2006 to 2018 received NAC at the Yonsei
Cancer Center, Seoul, South Korea. Patients with stage
III or IV ovarian carcinoma who received three cycles of
NAC followed by IDS were included in the study.
The exclusion criteria were as follows: Patients still re-
ceiving chemotherapy at the time of data analysis (N =
19); patients who had not received IDS after NAC (N =
15); patients for whom data was missing (N = 31); and,
lastly, patients who had not undergone a germline BRCA
test (N = 92). After this review, 169 patients met our cri-
teria. Of these, 122 patients had the wild-type BRCA
genotype, and 47 had BRCA1 or BRCA2 mutations
(Fig. 1).
Treatment
Most patients received taxane (paclitaxel, docetaxel) and
platinum (carboplatin) combination chemotherapy and
some patients received paclitaxel, carboplatin and beva-
cizumab combination chemotherapy. Other treatments
such as radiation or endocrine therapy were not per-
formed before surgery. Determination of which patients
required NAC was based on initial imaging studies that
showed high tumor dissemination with high risk of post-
operative comorbidities and poor performance status, or
optimal cytoreduction surgery (residual disease measur-
ing 1 cm or less) was unsuitable because of a high tumor
burden [predictive index value (PIV) ≥ 8] [15]. For diag-
nostic laparoscopy, the degree of tumor burden was de-
termined with the PIV [16]. For IDS, all patients
underwent surgery with the intent to achieve complete
resection with no residual tumor. Standard surgical pro-
cedures included hysterectomy, bilateral oophorectomy,
omentectomy, pelvic/para-aortic lymph node dissection,
and appendectomy. Radical surgery included more ag-
gressive procedures such as liver resection or bowel re-
section than those who underwent standard surgical
procedures [17]. Subsequently, additional cycles of adju-
vant chemotherapy were administered to complete a
total of six cycles at the discretion of the treating
Fig. 1 Flow diagram of the study population. NAC, neoadjuvant chemotherapy
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physician. Surgical complexity was classified as low,
intermediate, or high [18].
Pathologic review
The resected tissues were formalin-fixed and paraffin-
embedded, and stained with hematoxylin and eosin
(H&E) in the Department of Pathology, Severance Hos-
pital, Yonsei University College of Medicine. Three ex-
pert gynecologic pathologists reviewed all available
H&E-stained slides obtained from IDS tissues. They in-
dependently scored each slide according to the three-
tiered CRS system described by Böhm et al. [5]. Briefly,
CRS is defined as follows: CRS 1: No or minimal tumor
response; CRS 2: Partial tumor response: CRS 3:
Complete or near-complete tumor response.
BRCA testing
From the whole blood samples, genomic DNA was ex-
tracted according to the protocol provided by the manu-
facturer (QIAamp DNA Blood Mini Kit, QIAGEN,
USA). To assess the germline mutations in BRCA1 and
BRCA2, the entire coding region and intron-exon
boundaries of two genes were amplified using polymer-
ase chain reaction (PCR) amplification. We identified all
variants using Sanger sequencing on a 3730 DNA
Analyzer with the BigDye Terminator v3.1 Cycle Se-
quencing Kit (Applied Biosystems, Foster City, CA,
USA). Sequencing data were aligned against appropriate
reference sequences (accession numbers NM_007294
and NM_000059, respectively) and analyzed using the
Sequencher 5.3 software (Gene Codes Corp., Ann Arbor,
MI, USA). Variations were described following the no-
menclature system of the Human Genome Variation So-
ciety (http://www.hgvs.org/mutnomen) and the
conventional nomenclature system from the Breast Can-
cer Information Core (BIC; http://research.nhgri.nih.
gov/bic/). Pathogenicity interpretation of the variants
were performed according to 2015 American College of
Medical Genetics and Genomics guideline by profes-
sional medical geneticists, using evidences of variant
type assessment, population allele frequency, prediction
algorithm results, and database search such as Human
Gene Mutation Database, ClinVar, and BIC.
Statistical analysis
Descriptive data are reported as the median (range) or
frequency (percentage). Categorical variables were com-
pared with the chi-square or continuous variables with
the Student’s t-test or Mann-Whitney U test for para-
metric/non-parametric variables, respectively. Responses
were assessed according to the Response Evaluation Cri-
teria in Solid Tumors criteria, version 1.1. We defined
PFS as the time from the date of diagnosis to disease
progression or death; overall survival (OS) was measured
from the date of diagnosis to death or to the date of the
last follow-up. Survival analysis was performed using the
Kaplan-Meier method with a log-rank test. For all ana-
lyses, the significance level was set at 0.05. The statistical
analyses were performed with the SPSS statistical soft-
ware (version 21.0; IBM Corp., Armonk, NY).
Results
Patients’ characteristics
Table 1 contains a comparison of the clinical character-
istics between the BRCA wild-type genotype group and
the BRCA mutation group. Of the 169 patients included,
122 (71.9%) had the wild-type BRCA genotype, and 47
(28.1%) had the BRCA1/2 mutations. There were no sig-
nificant between-group differences in patient character-
istics such as age, CA-125 level, FIGO stage, histologic
type, tumor grade, tumor burden, CRS, residual disease,
rate of radical surgery, surgical complexity score, chemo-
therapy regimen, or cycles of NAC.
CRS relative to BRCA1/2 mutation status
CRS 3 patients were 43 (35.2%) and 16 (34.0%) for pa-
tients without and with BRCA1/2 mutations, respectively
(P = 0.516) (Table 2). Although CRS 3 rates differed be-
tween BRCA1 (26.9%), BRCA2 (42.9%) and the wild-type
BRCA genotype, these difference did not achieve statis-
tical significance.
Kaplan–Meier curves for OS and PFS stratified by
CRS in patients with the BRCA1/2 mutations are shown
in Fig. 2. Fifteen (48.4%) in the CRS 1/2 and 8 (50.0%) in
the CRS 3 group had recurred by the time of the ana-
lysis. Median PFS in the CRS 1/2 group was 21.7 months
(95% confidence interval [CI], 16.2–33.3) and 22.0
months (95% CI, 14.4–29.6) in the CRS 3 group. Four
(12.9%) in the CRS1/2 and no patients in the CRS3
group had died by the time of the analysis. Median OS
was not reached in both groups. CRS 3 in patients with
the BRCA1/2 mutations was not significantly associated
with improved PFS (P = 0.949) and OS (P = 0.168). In pa-
tients without BRCA mutations, 52 (65.8%) in the CRS
1/2 and 24 (55.8%) in the CRS 3 group had recurred by
the time of the analysis. Median PFS in the CRS 1/2
group was 17.2 months (95% CI, 14.7–19.7) and 22.4
months (95% CI, 14.5–30.3). Eighteen (22.8%) in the
CRS 1/2 and 5 (11.6%) patients in the CRS 3 group had
died by the time of the analysis. Median OS in the CRS
1/2 group was 96.4 months (95% C], 27.1–165.7) and
not reached in the CRS 3 group. However, CRS 3 in pa-
tients without BRCA mutations was significantly associ-
ated with improved PFS (P = 0.030) and OS (P = 0.039)
(Fig. 3). The results of the multivariate Cox regression
analyses of PFS and OS in all patients are shown in Add-
itional file 1. In terms of recurrence, multivariate ana-
lysis showed that BRCA1/2 mutation was a marginally
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significant prognostic factor (HR, 0.65; 95% CI, 0.40–
1.04). Multivariate analysis showed CRS 3 (HR, 0.29;
95% CI, 0.10–0.80) and BRCA1/2 mutation (HR, 0.27;
95% CI, 0.08–0.92) were significantly associated with a
longer OS.
We also categorized the patients based on BRCA mu-
tations and CRS (BRCA1/2 mutations with CRS 1/2; the
wild-type BRCA genotype with CRS 1/2; BRCA1/2 muta-
tions with CRS 3; and the wild-type BRCA genotype with
CRS 3) to evaluate survival according to the relationship
of BRCA1/2 mutations in the CRS. Fifteen (48.4%) in
BRCA1/2 mutations with CRS1/2, 52 (65.8%) in the
wild-type BRCA genotype with CRS1/2, 8 (50%) in
BRCA1/2 mutations with CRS3, and 24 (55.8%) in the
Table 1 Patient and clinical characteristics (N = 169)
Characteristics BRCA wild-type (N = 122) BRCA mutation (N = 47) P
Age, median (range), years 57 (32–77) 56 (27–76) 0.610
CA-125 level, median (range), U/mL 1958.7 (94.2.0–21,994.8) 1711.3 (75.0–23,919.0) 0.759
FIGO stage, n (%)
III 56 (45.9%) 23 (48.9%) 0.734
IV 66 (54.4%) 24 (51.1%)
Grading
1 3 (2.5%) 0 (0%) 0.489
2 11 (9.0%) 2 (4.5%)
3 102 (83.6%) 42 (89.4%)
Not available 6 (4.9%) 3 (6.4%)
Tumor burden assessed by diagnostic laparoscopy*
PIV 8 27 (22.1%) 3 (6.4%) 0.097
PIV 10 25 (20.5%) 14 (29.8%)
PIV 12 10 (8.2%) 4 (8.5%)
PIV 14 5 (4.1%) 1 (2.1%)
Not available 55 (45.1%) 25 (53.2%)
CRS, n (%)
1–2 79 (64.8%) 31 (66.0%) 0.516
3 43 (35.2%) 16 (34.0%)
Residual disease, n (%)
No 62 (50.8%) 18 (38.3%) 0.344
Any residual 58 (47.5%) 28 (59.6%)
Not available 2 (1.6%) 1 (2.1%)
Radical surgery†, n (%)
None 59 (48.4%) 19 (40.4%) 0.354
Any radical surgery 63 (51.6%) 28 (59.6%)
Surgical complexity score groups‡
1–2 (Low/intermediate) 102 (83.6%) 37 (78.7%) 0.457
8 (High) 20 (16.4%) 10 (21.3%)
Chemotherapy regimen, n (%)
Paclitaxel + carboplatin 91 (74.6%) 34 (72.3%) 0.576
Docetaxel + carboplatin 8 (6.6%) 6 (12.8%)
Weekly paclitaxel + carboplatin 15 (12.3%) 5 (10.6%)
Paclitaxel + carboplatin + bevacizumab 8 (6.6%) 2 (4.3%)
* According to Fagotti et al. [15]
† Radical surgery includes any of following: bowel surgery, cholecystectomy, diaphragm peritonectomy/resection, distal pancreatectomy video-assisted
thoracoscopic surgery, splenectomy, liver resection, supraclavicular fossa resection, ureter resection, and others
‡ According to Aletti et al. [19]
CA-125, cancer antigen 125; FIGO, International Federation of Gynecology and Obstetrics; HGSC, high-grade serous carcinoma; PIV, predictive index value; CRS,
chemotherapy response score
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wild-type BRCA genotype with CRS3 group had recurred
by the time of the analysis. Median PFS in 4 groups were
21.7 (95% CI, 16.2–33.3), 17.2 (95% CI, 14.7–19.7), 22.0
(95% CI, 14.4–29.6), and 22.4 (95% CI, 14.5–30.3), re-
spectively. Three (9.7%) in BRCA1/2 mutations with
CRS1/2, 18 (22.8%) in the wild-type BRCA genotype
with CRS1/2, 0 (0%) in BRCA1/2 mutations with CRS3,
and 5 (11.6%) in the wild-type BRCA genotype with
CRS3 group had died by the time of the analysis. Median
OS in the BRCA1/2 mutations with CRS3 group was
96.4 and other 3 groups were not reached. In patients
with CRS 1/2, the carriers of BRCA1/2 mutations had
better PFS (P = 0.044) and OS (P = 0.043) than the wild-
type BRCA genotype patients. However, in patients with
CRS 3, there was no significant difference in PFS (P =
0.863) and OS (P = 0.216) between BRCA1/2 carriers
and the wild-type BRCA genotype patients (Fig. 4). In
addition, we performed a subset analysis including only
in Grade 3 patients excluding the 16 patients with
Grade1 or 2. Similar results were obtained for patients
with Grade 3 (Additional file 2). In patients with CRS 1/
2, the carriers of BRCA1/2 mutations had better PFS
(P = 0.015) and OS (P = 0.049) than the wild-type BRCA
genotype patients. However, in patients with CRS 3,
there was no significant difference in PFS (P = 0.917)
and OS (P = 0.389) between BRCA1/2 carriers and the
wild-type BRCA genotype patients.
Discussion
In this study, we evaluated the relationship between
BRCA1/2 mutations and CRS and survival outcomes in
advanced-stage ovarian cancer patients treated with
NAC followed by IDS. The patients with BRCA1/2 mu-
tations did not show higher CRS rates than patients
without these mutations. In patients without the
BRCA1/2 mutations, the CRS 3 patients showed superior
survival outcomes compared to the patients with CRS 1/
2. In addition, in the CRS 1/2 patient group, the survival
outcomes of the BRCA1/2 carriers were superior to
those of the wild-type BRCA genotype patients. In the
BRCA wild-type group, patients who achieved CRS 1/2
after NAC had a poor prognoses compared to the pa-
tients with CRS 3. Therefore, patients with the BRCA
wild-type should be considered for additional treatments
Table 2 Chemotherapy response score relative to BRCA1/2
mutation status
CRS Wild type Mutation Total P value
BRCA1 or 2 1–2 79 (64.8%) 31 (66.0%) 110 (65.1%) 0.516
3 43 (35.2%) 16 (34.0%) 59 (34.9%)
BRCA1 1–2 91 (63.6%) 19 (73.1%) 110 (65.1%) 0.243
3 52 (36.6%) 7 (26.9%) 59 (34.9%)
BRCA2 1–2 98 (66.2%) 12 (57.1%) 110 (65.1%) 0.280
3 50 (33.8%) 9 (42.9%) 59 (34.9%)
CRS, Chemotherapy response score
Fig. 2 Kaplan-Meier curves of PFS (a) and OS (b) stratified by CRS in patients with BRCA1/2 mutations. CI, confidence interval; CRS, chemotherapy
response score; PFS, progression-free survival; OS, overall survival
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Fig. 3 Kaplan-Meier curves of PFS (a) and OS (b) stratified by CRS in patients without BRCA mutations. CI, confidence interval; CRS, chemotherapy
response score; PFS, progression-free survival; OS, overall survival
Fig. 4 Kaplan-Meier curves of PFS (a) and OS (b) stratified by BRCA mutations and CRS. CI, confidence interval; CRS, chemotherapy response
score; PFS, progression-free survival; OS, overall survival
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to achieve CRS 3 after NAC, such as adding a bevacizu-
mab or immune checkpoint inhibitors to platinum-
based NAC. In addition, BRCA wild-type patients with
CRS 1/2 after platinum-based NAC expected to have a
poor prognosis due to residual tumors after NAC that
may be resistant to platinum-based NAC if they receive
the same NAC regimen after IDS. To improve the sur-
vival of the BRCA wild-type patients with CRS 1/2, the
genomic profiles of the post-NAC tissues should be eval-
uated to identify biomarkers and to select targeted ther-
apies [19].
Response rates to platinum-based NAC predict sur-
vival and may be regarded as a surrogate prognostic
marker [5, 6]. A three-tiered CRS system showed a sig-
nificant association with survival outcomes. The CRS
system for assessing platinum-based NAC response rates
can be a reproducible prognostic tool, and the incorpor-
ation of the CRS system after NAC can help determin-
ation of adjuvant treatment in advanced-stage ovarian
cancer patients. Previous studies [10–12] showed that
advanced-stage ovarian cancer patients with BRCA1/2
mutations tend to have higher response rates to
platinum-based chemotherapy, longer PFS, and a higher
benefit from NAC. The BRCA1/2 mutations are also be-
ing considered as specific targets. Recent randomized
studies on poly (adenosine diphosphate–ribose) poly-
merase inhibitors have demonstrated a substantial sur-
vival benefit in BRCA1/2 carriers [20–24], hence
germline BRCA1/2 testing is becoming a mandatory in
treatment decisions in advanced-stage ovarian cancer.
In triple-negative breast cancer, several studies have
shown that in the relationships between germline
BRCA1/2 mutations, response rates, and prognoses. In
patients with triple-negative breast cancer, BRCA1/2
mutation patients had higher pCR rates than those with
BRCA wild-type patients. However, BRCA mutation pa-
tients do not benefit as much from a pCR compared
with patients without BRCA mutation. In ovarian cancer
patients, no such studies have yet been reported. Hah-
nen et al. [13] showed that triple-negative breast cancer
patients without germline BRCA1/2 mutations benefit
from the addition of carboplatin and that BRCA1/2 mu-
tation carriers had superior response rates. Fasching
et al. [14] showed the effect of BRCA1/2 mutations in
the NAC of triple-negative breast cancer. Patients with
BRCA1 or BRCA2 mutations had higher pCR rates than
patients without a mutation. However, BRCA1/2 muta-
tion patients who receive standard treatment do not
benefit as much from a pCR as patients with the wild-
type BRCA. These results were similar to our study.
Our study showed that patients with BRCA1/2 muta-
tions enjoyed a good survival outcome regardless of their
CRS. In contrast, CRS 3 had a significant survival benefit
on PFS and OS for wild-type BRCA genotype patients.
In addition, the BRCA1/2 mutations had a significant in-
fluence on survival in the CRS 1/2 patient group. One
plausible explanation for the absence of the effect of
CRS 3 on the prognoses for patients with the BRCA1/2
mutations is the influence of the platinum-based adju-
vant treatment after IDS. Although the CRS 1/2 group
of patients was expected to have a poor prognosis, their
prospects were improved if they had the BRCA1/2 muta-
tions because of their conferred sensitivity to platinum-
based adjuvant chemotherapy after IDS. The mechanism
of action by platinum drugs is mediated by the forma-
tion of the covalent binding of platinum to DNA. This
binding interferes with DNA synthesis and ultimately
leads to cell death [25]. It seems likely that partially
formed covalent bindings cause replication of fork
stalling when it is encountered by the DNA replica-
tion machinery during the S phase. These stalled rep-
lication forks may degenerate into double-stranded
DNA breaks [26] in which tumor cells with defects in
their DNA repair pathways achieves increased re-
sponse rates against platinum drugs, as investigated in
previous studies [27–30].
However, unlike in breast cancer studies, the status of
BRCA1/2 mutations in our study was unrelated to CRS.
In previous studies [31, 32], patients with germline
BRCA1/2 mutations were associated with wider disease
diffusion than BRCA wild-type patients in terms of peri-
toneal spread and incidence of bulky lymph nodes. Fur-
thermore, Soslow et al. [33] showed the correlations
between the genotype and characteristic morphologic
appearance of ovarian cancer. The BRCA1 mutation
group had more tumor-infiltrating lymphocytes, thus
suggesting that the status of BRCA mutations could in-
fluence the immunological microenvironment suffi-
ciently to eventually drive the specific characteristics of
disease presentation. Therefore, BRCA1/2 mutation car-
riers may have a lower CRS following NAC as compared
to BRCA wild-type patients.
The main limitation of our study was its low sample
size and the small number of patients with BRCA1/2
mutations. Although 169 patients were genotyped, there
were only 47 carriers of these mutations. Second, con-
sidering the family history of patients who were diag-
nosed with ovarian cancer before 2017, the germline
BRCA test was recommended for patients with a high
probability of being a BRCA1/2 mutation carrier. Ola-
parib treatment in the maintenance setting has been
covered by Korean National Health Insurance since
2017, we have been routinely offered the germline BRCA
test in patients diagnosed with high-grade serous ovarian
cancer. In addition, because 92 people did not receive
BRCA test during the study period, a selection bias may
have influenced the outcomes. Third, NAC was only in-
corporated into our institution in late 2010; thus, our
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cohort was limited by the short follow-up period.
Fourth, the type of NAC is important because CRS is af-
fected by the response to chemotherapy. About 75% of
patients received paclitaxel and carboplatin combination
chemotherapy in our study, an analysis of the relation-
ship between CRS and the type of NAC could not be
conducted. \.
Conclusion
In conclusion, in advanced-stage ovarian cancer patients
treated with NAC followed by IDS, CRS 3 was not asso-
ciated with increased survival for BRCA1/2 mutation
carriers than for patients without these mutations. Add-
itional studies are needed to elucidate the effect of CRS
on prognoses in advanced-stage ovarian cancer patients
with and without BRCA1/2 mutations.
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